Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 versus Investigator?s Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Investigator: Juan Carlos Ramos

Institutional Protocol #: 20120479

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase III

Enrolling Since: 5/14/2013

Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3 Expressing Hematologic Malignancies

Investigator: Ronan Swords

Institutional Protocol #: 20120908

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I

Enrolling Since: 5/9/2013

A Phase IB, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are 60 Years or Older

Investigator: Ronan Swords

Institutional Protocol #: 20120902

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I

Enrolling Since: 4/5/2013

C25003: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Investigator: Joseph Rosenblatt

Institutional Protocol #: 20120841

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase III

Enrolling Since: 3/28/2013

An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Investigator: Ronan Swords

Institutional Protocol #: 20120774

National Clinical Trials Identifier: NCT00911066

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I

Enrolling Since: 1/23/2013

DEFLECT-1: A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

Investigator: Michele Morris

Institutional Protocol #: 20120667

National Clinical Trials Identifier: NCT01691248

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase III

Enrolling Since: 1/18/2013

A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX for the Treatment of Patients with Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)

Investigator: Krishna Komanduri

Institutional Protocol #: 20110320

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 9/5/2012

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous hematopoietic Cell Transplants (HCTs)

Investigator: Krishna Komanduri

Institutional Protocol #: 20110112

National Clinical Trials Identifier: NCT01229267

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: N/A

Enrolling Since: 6/15/2012

NCBP 6637-01: A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients.

Investigator: Martin Andreansky

Institutional Protocol #: 20120231

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 6/11/2012

Phase 1b Open-Label Study of the Safety and Clinical Activity of Crizotinib (pf-02341066) in Tumors With Genetic Events Involving the Anaplastic Lymphoma Kinase (alk) Gene Locus

Investigator: Alexandra Stefanovic

Institutional Protocol #: 20110297

National Clinical Trials Identifier: NCT01121588

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I

Enrolling Since: 3/7/2012

A Multicenter Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Treated with Rituximab and Vincristine

Investigator: Alexandra Stefanovic

Institutional Protocol #: 20110605

National Clinical Trials Identifier: NCT01397825

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I/II

Enrolling Since: 3/2/2012

Phase II Study to Evaluate Fenofibrate Therapy in Patients With Relapsed/Refractory Multiple Myeloma who Have Failed at Least two Prior Therapies

Investigator: Denise Pereira

Institutional Protocol #: 20110069

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: N/A

Enrolling Since: 3/1/2012

Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy with Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma

Investigator: Juan Carlos Ramos

Institutional Protocol #: 20100391

National Clinical Trials Identifier: NCT01000285

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I/II

Enrolling Since: 7/26/2011

AMC PROTOCOL #053: Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Lymphoma

Investigator: Juan Carlos Ramos

Institutional Protocol #: 20100388

National Clinical Trials Identifier: NCT00598169

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Pilot/Feasibility

Enrolling Since: 6/9/2011

Elevated Health Risk Among Patients with Non-Hodgkin’s Lymphoma (NHL) and Their Caregivers: Pilot Study

Investigator: Youngmee Kim

Institutional Protocol #: 20100411

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: N/A

Enrolling Since: 5/18/2011

Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination with Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for Relapsed Epstein Barr Virus Associated Lymphoma

Investigator: Juan Carlos Ramos

Institutional Protocol #: 20090166

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 4/22/2011

AMC-075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma

Investigator: Juan Carlos Ramos

Institutional Protocol #: 20100787

National Clinical Trials Identifier: NCT01193842

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I/II

Enrolling Since: 2/11/2011

ECOG E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia. (SCCC 2009028)

Investigator: Deborah Glick

Institutional Protocol #: 20090473

National Clinical Trials Identifier: NCT00843882

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase III

Enrolling Since: 6/21/2010

SCCC 2008043: Phase II Study of Rituximab in Combination with Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and MESNA (R-MACLO/IVAM) in Patients with Previously Untreated Mantle Cell Lymphoma

Investigator: Izidore Lossos

Institutional Protocol #: 20080803

National Clinical Trials Identifier: NCT00878254

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 3/12/2009

Sccc 2006069: Multicenter Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large b-Cell Lymphoma Patients Treated With r-Chop

Investigator: Izidore Lossos

Institutional Protocol #: 20061138

National Clinical Trials Identifier: NCT00450385

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 2/7/2007

Phase II Study of Ibritumomab Tiuxetan (Zevalin) in Patients With Previously Untreated Marginal Zone Lymphoma (Sccc 2005133)

Investigator: Izidore Lossos

Institutional Protocol #: 20060078

National Clinical Trials Identifier: NCT00453102

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 2/27/2006

Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Ecog Treatment Trials for Leukemia or Related Hematologic Disorders

Investigator: Mark Goodman

Institutional Protocol #: 20043176

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: N/A

Enrolling Since: 8/12/2005

"Study of Blood, Tissue and Body Fluids of Viral Associated Malignancies"

Investigator: Juan Carlos Ramos

Institutional Protocol #: 20030608

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: N/A

Enrolling Since: 9/16/2003

Clinical and Pathologic Studies in non-Hodgkin's Lymphoma and Hodgkin's Disease (Sccc 2003043)

Investigator: Izidore Lossos

Institutional Protocol #: 20030255

National Clinical Trials Identifier: N/A

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: N/A

Enrolling Since: 6/11/2003